Clinical trial · Observational
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
While thoracic radiation therapy (TRT) has been a primary component in successful treatment of Hodgkin lymphoma, exposure to this treatment has been associated with significant cardiovascular, cerebrovascular, and pulmonary morbidity in long-term survivors. Survivors of Hodgkin lymphoma (HL) are also at risk for fatigue and excessive daytime sleepiness. Insufficient sleep is recognized as an important public health concern, and is associated with cardiovascular disease, diabetes, obesity, neurocognitive problems, and reduced quality of life and productivity. Survivors of HL, who are already at risk for cardiac and neurologic morbidity due to their treatment exposures, could face catastrophic cardiovascular and cerebrovascular events with the added risk associated with obstructive sleep apnea (OSA). The investigators propose to examine indices of sleep quality using polysomnography, and associated neurocognitive performance, brain MRI, and structure and strength of neck muscles in 220 long-term adult survivors of Hodgkin lymphoma treated with thoracic radiation. OBJECTIVES: 1. To estimate the prevalence of OSA in adult survivors of HL treated with thoracic radiation, and compare the frequency to community controls matched on age, gender, race and body mass index. 2. To identify specific therapeutic factors associated with OSA in adult survivors of HL treated with thoracic radiation. 3. To identify biomarkers of OSA in adult survivors of HL treated with thoracic radiation. 4. To examine associations between OSA and cardiac morbidity and brain integrity in the adult survivors of HL treated with thoracic radiation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Obstructive Sleep Apnea | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Hodgkin Lymphoma
- description
- Participants will be survivors of Hodgkin Lymphoma (HL) who were treated with thoracic radiation during the course of their HL, who meet eligibility criteria, and who consent to this study.
- label
- Control Group
- description
- The Comparison or control group members will be recruited from healthy parents, sibling, relative or friends who accompany the participant for follow-up at SJCRH and who meet eligibility criteria.
Primary outcomes (1)
- measure
- Number of participants with obstructive sleep apnea (OSA) compared between groups
- timeFrame
- Once, at enrollment
- description
- The comparison will be between the Hodgkin lymphoma survivors and race, age, sex, body mass index (BMI) matched control group on frequency of OSA. OSA will be deemed present if either of two conditions is met: (1) polysomnography reveals an apnea hypopnea index (AHI) ≥ 15, or (2) polysomnography reveals an AHI ≥ 5 and the participant presents with clinical symptoms.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
HODGKIN LYMPHOMA SURVIVOR ELIGIBILITY CRITERIA Inclusion Criteria (Hodgkin Lymphoma Survivor): * Current participant in the SJLIFE clinical trial ongoing at St. Jude Children's Research Hospital (SJCRH) and was treated with thoracic radiation for Hodgkin lymphoma * Currently ≥ 18 years of age * ≥ 5 years from original diagnosis Exclusion Criteria (Hodgkin Lymphoma Survivor): * History of cranial or total-body radiation therapy * History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine. * History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment * History of a neurodevelopmental disorder or birth complication associated with neurocognitive impairment * History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the PIs * Currently pregnant * Secondary central nervous system (CNS) neoplasm COMPARISON GROUP (CONTROL) ELIGIBILITY CRITERIA Inclusion Criteria (Comparison Group): * Research participant is a sibling, parent, relative or friend of a current or former St. Jude patient * Research participant must be at least 18 years of age at the time of the scheduled evaluation Exclusion Criteria (Comparison Group): * History of cranial, total-body or thoracic radiation therapy * History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine. * History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment * History of a neurodevelopmental disorder or birth complication associated with neurocognitive impairment * History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the PIs * Currently pregnant * History of cancer * 1st degree relative of a survivor included in the current study.
References
Publications (0)
Data not yet available